Metabolism and Weight

GLP-1 Medications: The Complete Guide

GLP-1 medications explained: how semaglutide and tirzepatide work, trial results, side effects, muscle loss and what happens after stopping.

By Dr. Samia McCully, ND · Updated October 23, 2026

GLP-1 medications are prescription drugs that mimic glucagon-like peptide-1, a gut hormone that signals fullness, slows stomach emptying and supports insulin release after meals. They belong to the incretin class of medications, first developed for type 2 diabetes and now approved for weight management. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) produce average weight loss of roughly 15 to 21 percent in clinical trials. About 12 percent of U.S. adults reported currently taking a GLP-1 drug in a November 2025 KFF poll. Most lost weight returns after stopping, which makes the metabolic drivers that weight loss resistance treatment addresses central to long-term results.

GLP-1 Medications Available Today

GLP-1 medications differ in their active ingredient, form and approved uses. The main options:

Medication	Active ingredient	Form	Approved for weight management
Wegovy	Semaglutide	Weekly injection	Yes, 2021
Wegovy pill	Semaglutide	Daily tablet, 25 mg	Yes, December 22, 2025
Ozempic	Semaglutide	Weekly injection	Type 2 diabetes
Zepbound	Tirzepatide	Weekly injection	Yes, November 2023
Mounjaro	Tirzepatide	Weekly injection	Type 2 diabetes
Saxenda	Liraglutide	Daily injection	Yes

Tirzepatide acts on two receptors, GLP-1 and GIP, which contributes to its larger average weight loss. Compounded versions of semaglutide and tirzepatide spread widely during national shortages, which the FDA declared resolved for tirzepatide in December 2024 and for semaglutide in February 2025, limiting the legal basis for mass compounding. Compounded products are not FDA-approved and vary in quality.

How GLP-1 Medications Work

GLP-1 medications act on the same receptors as the body's own GLP-1 hormone, which the intestine releases after eating, but they last far longer. Five mechanisms produce their effects:

Appetite centers in the brain respond with stronger fullness signals and less interest in food, often described by users as quieter "food noise."
Slower stomach emptying keeps food in the stomach longer, extending fullness.
Glucose-dependent insulin release increases insulin only when glucose rises, which lowers blood sugar with little risk of lows when used alone.
Reduced glucagon lowers the liver's glucose output.
Dose escalation over several months raises the dose gradually to limit side effects.

Because the drugs work by reducing appetite, people eat less without the hunger that usually accompanies dieting, which explains both their effectiveness and the return of appetite when they stop.

Outcomes From Clinical Trials

Clinical trials show large average effects on weight and, for semaglutide, on cardiovascular risk. The landmark results:

STEP 1 enrolled 1,961 adults with obesity or overweight. Weekly semaglutide 2.4 mg produced an average weight loss of 14.9 percent at 68 weeks, compared with 2.4 percent on placebo (Wilding and colleagues, New England Journal of Medicine, 2021).
SURMOUNT-1 found average weight loss of 20.9 percent at 72 weeks on the highest dose of tirzepatide (Jastreboff and colleagues, New England Journal of Medicine, 2022).
OASIS 4 found 16.6 percent weight loss at 64 weeks with oral semaglutide 25 mg, compared with 2.7 percent on placebo, the basis for the 2025 approval of the Wegovy pill.
SELECT followed 17,604 adults with cardiovascular disease and overweight or obesity, and semaglutide reduced major cardiovascular events by 20 percent (Lincoff and colleagues, New England Journal of Medicine, 2023).
Metabolic markers, including A1C, blood pressure and some lipids, improved alongside weight.

Averages hide wide individual variation: some people lose far more than the average and others lose little.

Risks and Limits of GLP-1 Medications

GLP-1 medications carry side effects and practical limits that shape who stays on them. The main concerns:

Gastrointestinal effects. In STEP 1, 44.2 percent of semaglutide users reported nausea, compared with 17.4 percent on placebo. Diarrhea, vomiting and constipation are also common, mostly during dose increases.
Muscle loss. Body composition substudies show that part of the weight lost is lean mass, which matters for strength, metabolism and aging.
Weight regain after stopping, covered below.
Rare serious risks, including pancreatitis, gallbladder disease and a boxed warning about thyroid C-cell tumors seen in rodents, which rules the drugs out for people with a personal or family history of medullary thyroid cancer.
Cost and access. Insurance coverage varies widely, and many people stop because of cost.

These limits explain why many people look for ways to protect results during treatment and after stopping.

Support Strategies During and After GLP-1 Treatment

Support strategies protect muscle, steady blood sugar and prepare appetite regulation for life after medication. The strategies with the most support:

Protein at each meal, which helps preserve lean mass when total intake falls.
Resistance training two to three times a week to maintain muscle and strength.
Blood sugar habits, such as balanced meals and post-meal walks, described in the blood sugar and energy guide.
Hunger awareness, learning to distinguish physical hunger from habit and emotion, as covered in the hunger and mindful eating guide.
Sleep, since short sleep raises hunger hormones that the medication otherwise suppresses.

Decisions to reduce or stop a GLP-1 medication belong with the prescribing clinician. Wellness Architecture's programs do not use GLP-1 medications. They work on blood sugar, insulin resistance, thyroid function, sleep and hunger, with a continuous glucose monitor for every program patient. In a published testimonial, a patient named Julie described losing about 50 pounds without a GLP-1 drug.

Julie: 50 pounds, no Ozempic 2:18

GLP-1 Medications Produce Large Average Weight Loss

GLP-1 medications produce more weight loss than any previous class of obesity drugs, with averages of about 15 percent for semaglutide and about 21 percent for tirzepatide in major trials. These results exceed what most people achieve with diet changes alone over the same period. The effect comes mainly from reduced appetite and food intake. For people with obesity-related disease, the size of this effect carries real medical value.

Most Lost Weight Returns After Stopping

Weight regain after stopping GLP-1 medication is common. In the STEP 1 extension, 327 participants who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost within one year, ending with a net loss of 5.6 percent from their starting weight. Blood pressure and other metabolic improvements also reversed. The study's authors concluded that ongoing treatment is required to maintain the benefits, which frames the drugs as long-term therapy for most users.

Part of the Weight Lost Is Muscle

Rapid weight loss of any kind removes some muscle along with fat, and GLP-1 medications are no exception. Body composition substudies using DXA scans show that lean mass accounts for part of the total weight lost. Muscle loss lowers resting energy use and strength, and it contributes to faster regain after stopping. Adequate protein and regular resistance training reduce the share of weight lost as muscle.

GLP-1 Medications Reduce Cardiovascular Events in High-Risk Adults

The SELECT trial showed that semaglutide reduced heart attacks, strokes and cardiovascular deaths by 20 percent in 17,604 adults with established cardiovascular disease and overweight or obesity. This benefit led to an expanded approval for cardiovascular risk reduction. The finding applies to people with existing heart disease and does not show the same benefit in lower-risk people.

Access and Cost Shape Who Stays on Treatment

Access and cost determine how long many people stay on GLP-1 medications. In KFF's November 2025 poll, 18 percent of U.S. adults reported ever taking a GLP-1 drug and 12 percent reported current use, and half of users described the drugs as difficult to afford. Insurance coverage for weight management varies by plan. When coverage ends or costs rise, people stop, often before they have built the habits and metabolic changes that protect their results.

Frequently Asked Questions

How do GLP-1 medications work?

GLP-1 medications mimic the gut hormone GLP-1, strengthening fullness signals in the brain, slowing stomach emptying and increasing insulin release when glucose rises. People feel full sooner and think about food less, which lowers intake. Tirzepatide also acts on the GIP receptor.

How much weight do people lose on GLP-1 drugs?

People lose an average of about 15 percent of body weight on semaglutide 2.4 mg over 68 weeks and about 21 percent on the highest dose of tirzepatide over 72 weeks, according to the STEP 1 and SURMOUNT-1 trials. Individual results vary widely around these averages.

What happens after stopping a GLP-1?

After stopping a GLP-1, appetite returns and most people regain weight. In the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of stopping semaglutide, and metabolic improvements reversed. Decisions about stopping belong with the prescribing clinician.

What are the side effects of GLP-1 medications?

Common side effects of GLP-1 medications include nausea, diarrhea, vomiting and constipation, reported by 44.2 percent of semaglutide users for nausea in STEP 1. Rare serious risks include pancreatitis and gallbladder disease, and the drugs carry a boxed warning related to thyroid C-cell tumors.

How is muscle protected on a GLP-1?

Muscle on a GLP-1 medication is protected by eating adequate protein at each meal and doing resistance training two to three times a week. These steps reduce the share of weight lost as lean mass, which supports strength and metabolism and lowers the risk of regain.

Common Misconceptions About GLP-1 Medications

Misconception: GLP-1 Drugs Fix The Cause Of Weight Gain

GLP-1 drugs suppress appetite while they are taken, but they do not correct insulin resistance, sleep loss, thyroid problems or eating patterns on their own. The STEP 1 extension showed most weight returning after stopping. Underlying drivers remain when the medication ends.

Misconception: Weight Stays Off After Stopping

Participants in the STEP 1 extension regained about two-thirds of their lost weight within one year of stopping semaglutide. Appetite and metabolic markers returned toward previous levels. Maintaining results without the drug requires other strategies.

Misconception: All Weight Lost On GLP-1s Is Fat

DXA substudies show that part of the weight lost on GLP-1 medications is lean mass. Losing muscle lowers metabolic rate and strength. Protein and resistance training reduce this loss.

Misconception: Compounded Versions Are Identical To Approved Drugs

Compounded semaglutide and tirzepatide are not FDA-approved, and their strength, purity and formulation vary between pharmacies. The FDA declared the national shortages that justified mass compounding resolved in December 2024 and February 2025.

Misconception: GLP-1s Make Diet And Exercise Unnecessary

GLP-1 medications reduce intake, but food quality, protein, resistance training and sleep still determine body composition and long-term health. People who build these habits during treatment protect more muscle and keep more weight off.

Ongoing Debates in GLP-1 Treatment

Lifelong and time-limited use divide experts. One side treats obesity as a chronic disease requiring indefinite medication, citing regain after stopping. The other side favors time-limited use paired with lifestyle and metabolic change, citing cost, side effects and unknown long-term effects.

First-line use prompts disagreement. Some clinicians start medication early for people with obesity-related disease. Others start with metabolic and lifestyle treatment, adding medication if needed.

Compounded access draws strong views. Supporters cite affordability during shortages. Regulators and many clinicians cite quality and safety concerns now that approved supply has stabilized.

The significance of muscle loss remains debated. Some researchers argue that lean mass loss on GLP-1s resembles other forms of weight loss. Others warn of greater risk in older adults with limited muscle reserves.

Natural GLP-1 boosting divides practitioners. Protein- and fiber-rich meals raise the body's own GLP-1 modestly. Supplements marketed as natural GLP-1 alternatives lack evidence of comparable effects.

Components of GLP-1 Treatment

GLP-1 treatment contains several connected parts. The GLP-1 hormone forms a component of the incretin system, which links eating to fullness and insulin release. Appetite suppression forms the central component of the drug effect. Dose escalation forms a component of treatment, raising the dose over months to limit side effects. Lean mass forms a component of the weight lost, and protein intake forms a component of muscle preservation alongside resistance training. Long-term outcomes depend on how these parts are managed during treatment and after it ends.

Summary

GLP-1 medications mimic a gut hormone to reduce appetite and produce average weight loss of about 15 to 21 percent in trials. The available medications, their mechanisms, trial outcomes, risks and support strategies together define their role. GLP-1 medications produce large average weight loss, but most lost weight returns after stopping and part of the loss is muscle. Weight loss resistance treatment addresses the metabolic drivers that medication alone leaves in place.